CATALYST PHARMACEUTICAL PARTNERS, INC. Form 8-K/A January 04, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 26, 2012

CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware (State or other jurisdiction

001-33057 (Commission 76-0837053 (I.R.S. Employer

of incorporation) File Number) Identification No.)

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K/A


355 Alhambra Circle

Suite 1500

Coral Gables, Florida 33134
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K/A

Item 1.01 Entry Into a Material Definitive Agreement

On October 31, 2012, the Company filed a Form 8-K in connection with its entering into a License Agreement, dated as of October 26, 2012 (the License Agreement), with BioMarin Pharmaceutical, Inc. (BioMarin). This Form 8-K/A amends the original Form 8-K as filed to file another redacted copy of the License Agreement pursuant to the Company s request for confidential treatment with the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 10.1 License Agreement, dated as of October 26, 2012, between BioMarin Pharmaceutical, Inc. and Catalyst Pharmaceutical Partners, Inc. (portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande Alicia Grande Vice President, Treasurer and CFO

Dated: January 3, 2013